On Friday, September 11, the FDA announced their approval of the first laboratory test that, prior to exploratory surgery or biopsy, can indicate the likelihood of ovarian cancer, even if radiological tests fail to indicate malignancy. The announcement comes at a fitting time—during September—the month recently designated by President Obama as National Ovarian Cancer Awareness Month.